General antioxidant pathway

The 'General antioxidant pathway' refers to a therapeutic mechanism focused on the mitigation of oxidative stress rather than the modulation of a specific protein target. This approach typically involves the direct scavenging of reactive oxygen species (ROS) or the indirect upregulation of endogenous antioxidant defenses, such as the Nrf2-ARE signaling axis (Forman & Zhang, 2021, Nature Reviews Drug Discovery). While oxidative damage is implicated in the pathogenesis of neurodegenerative and cardiovascular diseases, the clinical success of general antioxidants has been limited by the 'antioxidant paradox,' where the removal of ROS interferes with necessary physiological signaling (Halliwell, 2012, Nutrition Reviews). Drugs associated with this effect, such as edaravone or N-acetylcysteine, often exhibit pleiotropic actions that make identifying a single primary molecular target difficult (Sies, 2017, Redox Biology). Consequently, this classification is used when the therapeutic benefit is derived from broad redox modulation across multiple indirect pathways. In a biotech context, this target description serves as a placeholder for compounds whose efficacy is linked to systemic antioxidant capacity rather than high-affinity binding to a discrete receptor or enzyme.

Other names

Antioxidant effectROS scavengingIndirect antioxidant pathwaysRedox modulationCytoprotective antioxidant signaling

Neutralization of reactive oxygen species (ROS) and induction of endogenous antioxidant enzymes (e.g., SOD, CAT, GPx) via pathways such as Nrf2-ARE (Forman & Zhang, 2021).